Japan's Corporate News Network reported today:
Astellas Pharma announced on November 29 that it has filed a lawsuit against Toyo Pharmar and Aska Pharmaceutical for infringement on Astellas' patents on tamsulosin hydrochloride in the Tokyo District Court. The suit seeks monetary damages and an injunction of infringing products, namely Restream Capsules 0.1mg/0.2mg currently marketed by the two respective companies.
Astellas Pharma claims that it holds a formulation patent of tamsulosin hydrochloride that expires in March 2006. Tamsulosin hydrochloride is a selective alpha-1 blocker indicated for the treatment of urinary disturbance.
Currently, Astellas Pharma is marketing a sustained-release formation of tamsulosin hydrochloride under the trade name of Harnal 0.1mg/0.2mg Capsules.